Status: Not yet recruiting
The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This is a multi-center, single-arm, open-label, early exploratory clinical study. The objective of this study is to evaluate the safety and preliminary efficacy of KSVCBD injection in AQP4-positive Neuromyelitis Optica Spectrum Disorder
Participants needed: 18
Trial details
Phase: Early Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Chinese PLA General HospitalUpdated: May 18, 2026Locations: 1
Eligibility criteria
Patients must meet the 2015 International Consensus Diagnostic Criteria for Neur... [+4]
Viral infections: Known HIV, active HBV, or active HCV. [+5]